T2 Biomarkers as Predictors of Exacerbations of Chronic Obstructive Pulmonary Disease

Alcázar‐Navarrete, Bernardino; López, J. Cristóbal; Flores, Paula García; Antelo, M. Ortega; Cruz, Ivan Aguilar; Rodríguez, Oliverio Ruiz; Díaz, Pilar; Palacios, Pedro Romero

doi:10.1016/j.arbres.2021.11.006

Cited by 8 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Firstly, we recruited COPD patients from a single hospital which might have introduced selection bias and limited the number of patients. Secondly, the patient group in this study tended to have mild COPD compared to that in other studies [7,20]. On the other hand, blood eosinophil levels in the patient cohort of this study were around 200 cells/μL, similar to previous reports [31].…”

Section: Discussionsupporting

confidence: 84%

See 1 more Smart Citation

Blood Eosinophil Count as a Predictive Biomarker of Chronic Obstructive Pulmonary Disease Exacerbation in a Real-World Setting

Komura

Satô

Suzuki

et al. 2023

Canadian Respiratory Journal

View full text Add to dashboard Cite

Introduction. Chronic obstructive pulmonary disease (COPD) is the third leading cause of death, and COPD exacerbation worsens the prognosis. Eosinophilic airway inflammation is a COPD phenotype that causes COPD exacerbation and is correlated with peripheral blood eosinophil count. We analyzed real-world data of COPD patients to assess the risk factors of COPD exacerbation focusing on blood eosinophils. Materials and Methods. Patients with COPD who visited our hospital between January 1, 2018, and December 31, 2018, were recruited, and their background information, spirometry data, laboratory test results, and moderate-to-severe exacerbation events during the one-year follow-up period were collected from the electronic medical records and analyzed. The COPD exacerbation risk factors were assessed using univariate and multivariate logistic regression analyses. Results. Twenty-two of 271 (8.1%) patients experienced moderate-to-severe exacerbation. Patients with exacerbation showed worse pulmonary function, and we found that a high blood eosinophil count (≥350 cells/μL; p = 0.014 ), low % FEV1 (<50%; p = 0.002 ), increase in white blood cell (≥9000 cells/μL; p = 0.039 ), and use of home oxygen therapy ( p = 0.005 ) were risk factors for future exacerbations. We also found a strong correlation between eosinophil count cut-offs and exacerbation risk (r = 0.89, p < 0.001 ). On the other hand, there was no relation between exacerbation risk and inhalation therapy for COPD. Conclusion. In a real-world setting, peripheral blood eosinophil count could be a predictor of future COPD exacerbation.

show abstract

Section: Discussionsupporting

confidence: 84%

“…In contrast, the usefulness of blood eosinophil count for predicting COPD exacerbation is controversial. Recent studies reported that blood eosinophil count can be a useful predictor of future exacerbations [18][19][20]. Nevertheless, real-world evidence of blood eosinophil count as a predictor of COPD exacerbation is insufcient.…”

Section: Introductionmentioning

confidence: 99%

Blood Eosinophil Count as a Predictive Biomarker of Chronic Obstructive Pulmonary Disease Exacerbation in a Real-World Setting

Komura

Satô

Suzuki

et al. 2023

Canadian Respiratory Journal

View full text Add to dashboard Cite

show abstract

“…Chronic obstructive pulmonary disease (COPD) is a common, frequently occurring, major, and difficult disease of the chronic respiratory system [ 1 ]. It has a huge disease burden and has attracted more and more attention in recent years [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

[Retracted] The Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol in the Treatment of COPD in the Elderly

Guo

Chen

2022

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

Objective. Chronic obstructive pulmonary disease (COPD) is a major and difficult disease of the chronic respiratory system that is common and frequent, with a huge disease burden. The aim of this study was to investigate the efficacy and safety of budesonide/glyburide/formoterol fumarate (BGF) in the treatment of COPD. Methods. A comprehensive literature search was conducted in PubMed, Embase, Cochrane Library, and Web of Science. The basic features of the seven pieces of literature were identified using the search strategy. The sample size range was 130∼1264. Results. The effects of BGF increased FEV1 in patients with COPD (mean difference = 2.86, 95%CI: 2.71–3.01, p < 0.00001 ). The effects of BGF improved in patients with ≥1 TEAE in patients with COPD, and was not statistically significant after treatment (Odds rate = 1.00, 95%CI: 0.85–1.17, p = 0.97 ). The effects of BGF increased in patients with TEAEs related a to study treatment in patients with COPD (odds rate = 1.27, 95% CI: 1.03–1.57, p = 0.02 ). The effects of BGF in decreased patients with serious TEAEs in patients with COPD (odds rate = −0.02, 95% CI: −0.03–−0.00, p = 0.04 ). The effects of BGF decreased the death rate in patients with COPD, and were not statistically significant after treatment (odds rate = 0.77, 95% CI: 0.31–1.97, p = 0.59 ). The effects of BGF decreased the hypertension rate in patients with COPD (odds rate = 0.92, 95% CI: 0.44–1.89, p = 0.81 ), and was not statistically significant after treatment. The effects of BGF increased pneumonia in patients with COPD (odds rate = 1.55, 95% CI: 0.81–2.97, p = 0.19 ), and were not statistically significant after treatment. The effects of BGF increased FEV1, increased patients with TEAEs related a to study treatment, and decreased patients with serious TEAEs in patients with COPD. Conclusion. This study elucidates the efficacy and safety of BGF in the treatment of COPD with a view to providing a clinical reference.

show abstract

“…However, some cohort studies have reported that the correlations between these two biomarkers combined and acute exacerbation were not statistically significant [ 35 ]. In addition, a recent study reported that combining FeNO and blood eosinophil count could enhance the detection of future exacerbation of COPD [ 50 ]. There are several causes of these discrepancies.…”

Section: Discussionmentioning

confidence: 99%

The Combined Value of Type2 Inflammatory Markers in Chronic Obstructive Pulmonary Disease

Liu

Guo

Mou

et al. 2022

JCM

View full text Add to dashboard Cite

The roles of type2 inflammatory markers in chronic airway diseases have been assessed in previous studies. However, the relationship between the combined value of these biomarkers and chronic obstructive pulmonary disease (COPD) has not been fully elucidated. We aimed to investigate the roles of the combined value of the fraction of exhaled nitric oxide (FeNO) level and blood eosinophil count in COPD and the predictive capability of these biomarkers. In total, 266 patients were included in our analysis. When the two type2 biomarkers were assessed separately, there were limited correlations between either increased FeNO level or blood eosinophil count and decreased incidence of total exacerbation or frequency of mild exacerbation. Combining these two biomarkers strengthened their association with both incidence and frequency of acute exacerbation. In addition, during further assessment, simultaneously increased FeNO level and blood eosinophil count were associated with both mild and moderate acute exacerbation. Among the subjects included in this analysis, although the predictive capability was improved when these two biomarkers were combined, the improvement was not statistically significant, indicating the need to increase the sample size. The combination of FeNO level and blood eosinophil count exhibited strong and independent additive value in the assessment of acute exacerbation in COPD; simultaneously increased FeNO level and blood eosinophil count played a protective role in progression of COPD.

show abstract

T2 Biomarkers as Predictors of Exacerbations of Chronic Obstructive Pulmonary Disease

Cited by 8 publications

References 24 publications

Blood Eosinophil Count as a Predictive Biomarker of Chronic Obstructive Pulmonary Disease Exacerbation in a Real-World Setting

Blood Eosinophil Count as a Predictive Biomarker of Chronic Obstructive Pulmonary Disease Exacerbation in a Real-World Setting

[Retracted] The Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol in the Treatment of COPD in the Elderly

The Combined Value of Type2 Inflammatory Markers in Chronic Obstructive Pulmonary Disease

Contact Info

Product

Resources

About